Orchestra BioMed Holdings, Inc. (OBIO)
(Delayed Data from NSDQ)
$6.70 USD
+0.02 (0.30%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.71 +0.01 (0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
OBIO 6.70 +0.02(0.30%)
Will OBIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OBIO
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
OBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Fortrea Holdings Inc. (FTRE) Q2 Earnings Expected to Decline
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy?
Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know
Other News for OBIO
OBIO Crosses Above Key Moving Average Level
Orchestra BioMed initiated with bullish view at H.C. Wainwright, here's why
Orchestra BioMed reports Q2 results
Piper Sandler Remains a Buy on Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update